Cyclic AMP response element-binding protein and depression

Expert Review of Neurotherapeutics

Volumn 2, Issue 3, 2002, Pages 347-354

  Thome, Johannes ^a   Henn, Fritz A ^a   Duman, Ronald S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Affective disorder; Antidepressant drug; CAMP; CREB; Depression; Mood; Psychosis; Signal transduction; Therapy; Transcription factor

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DENBUFYLLINE; DESIPRAMINE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NORADRENALIN; PAPAVERINE; REBOXETINE; ROLIPRAM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL FEATURE; CYCLIC AMP RESPONSIVE ELEMENT; DEPRESSION; GENE EXPRESSION; HUMAN; NERVE CELL PLASTICITY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 0036279825     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.3.347     Document Type: Review

References (85)

1. Epidemiology of depression
2. Depressive disorders in the medically ill: An overview
3. Molecular genetics in affective illness
4. Genetics of psychiatric disease
5. The catecholamine hypothesis of affective disorders: A review of supporting evidence
6. The biochemistry of affective disorders
7. The serotonin hypothesis of major depression: A review
8. DST non-normalization, clinical recovery and symtpomatic relapse
9. Neuroendocrinology and mood disorders
10. The immune pathophysiology of major depression
11. The past and future of cognitive therapy
12. Life-events and endogenous depression
13. Neuropsychological abnormalities in depression: Relation between brain and behaviour
14. SNaRIs, NaSSAs and NaRIs: New agents for the treatment of depression
15. Acute and maintenance treatment of chronic depression
16. Research and treatment approaches to depression
17. Novel therapeutic approaches beyond the 5-HT receptor
18. Regulation of cAMP-inducible genes by CREB
19. Cyclic adenosine 3′,5′-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins
20. A molecular and cellular theory of depression
21. Neural plasticity to stress and antidepressant treatment
22. Calcium signaling in neurons: Molecular mechanisms and cellular consequences
23. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
24. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families
25. G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: Effects of diagnosis, suicide and treatment at the time of death
26. Neuroplasticity and cellular resilience in mood disorders
27. Abnormalities of cAMP signaling in affective disorders: Implication for pathophysiology and treatment
28. Depresssion. Emerging insights from neurobiology
29. Stress, glucocorticoids and damage to the nervous system: The current state of confusion
30. Hippocampal atrophy in recurrent major depression
31. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression
32. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions
33. Hypercorrisolemia, hippocampal glucocorticoid receptors and fast feedback
34. Antidepressant treatments in the 21st century
35. Stress alters the expression of brain-derived neurotrophic factor and neurotrophin- 3 mRNAs in the hippocampus
36. Proliferation of granule cell precursors in the dentate gyrus of adult monkey is diminished by stress
37. Glial reduction in the subgenual prefrontal cortex in mood disorders
38. Hippocampal volume reduction in major depression
39. Neuronal plasticity and survival in mood disorders
40. Atrophy of the hippocampus in posttraumatic stress disorder: How and when?
41. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression
42. Stress differentially regulates synaptophysin and synaptotagmin expression in hippocampus
43. Reduced activation and expression of ERK1/2 MAPK in the post-mortem brain of depressed suicide subjects
44. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia
45. Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium
46. Subgenual prefrontal cortex abnormalities in mood disorders
47. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
48. Stress-induced changes in cerebral metabolites, hippocampal volume and cell proliferation are prevented by antidepressant treatment with tianeptine
49. Structural plasticity: Cause, result, or correlate of depression
50. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors
51. Clinical effects of the neurotrophic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports
52. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID
53. Amantadine: An antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme
54. Efficacy of papaverine addition in treatment-refractory major depression
55. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex
56. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA 1 of hippocampus
57. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment
58. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect
59. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens
60. A role for 5-HT in the action of antidepressant drugs
61. Noradrenaline involvement in antidepressant action
62. Chronic electroconvulsive treatment augments coupling of the GTP-binding portein Gs to the catalytic moiety of adenyl cyclase in a manner similar to that seen with chronic antidepressant drugs
63. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
64. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments
65. Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor
66. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism
67. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses
68. Neurotrophins and depression
69. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication
70. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I
71. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'
72. Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex
73. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats
74. Opposing effects of morphine and the neurotrophins, NT-3, NT-4 and BDNF, on locus coeruleus neurons in vitro
75. Antidepressant-like effect of brain derived neurotrophic factor (BDNF)
76. BDNF promotes the survival and sprouting of serotonergic axons in the rat brain
77. Mossy fiber sprouting and synaptic reorganization induced by chronic administration of electroconvulsive seizure: Role of BDNF
78. Neurogenesis in the adult human hippocampus
79. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
80. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression
81. Current advances and trends in the treatment of depression
82. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors
83. Antidepressant-like effects of rolipram and other inhibitors of cyclic AMP phosphodiesterase on behavior maintained by differential reinforcement of low response rate